|
Digoxin Clinical Trials
4 actively recruiting trials across 3 locations
▲ +1 trial since August 2026
Pipeline
Phase 1: 1Phase 2: 2Phase 4: 1
Top Sponsors
- Yale University1
- Hospital General de Agudos "Dr. Cosme Argerich"1
- H. Lee Moffitt Cancer Center and Research Institute1
- Eli Lilly and Company1
Indications
- Cancer2
- Fatty Liver Disease, Nonalcoholic1
- Acute Heart Failure (AHF)1
- Liver Disease1
- MASH With Fibrosis1
Other1 trial
Birmingham, Alabama1 trial
Digoxin Medulloblastoma Study
University of Alabama at Birmingham Children's of Alabama
Phase 2
Tucson, Arizona1 trial
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
University of Arizona - Cancer Center
Phase 1
New Haven, Connecticut1 trial
Digoxin In NASH (CODIN)
Yale New Haven Health
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.